Moonlight Bio harnesses evolutionary T cell adaptations found within human biology to enhance T cell potency. This science focuses on identifying adaptations that increase T cell proliferation, persistence, and function for therapeutic use. The company develops T cell therapies designed to achieve superior outcomes for cancer patients.
Funding
$14M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current T cell therapies for cancer treatment face challenges in achieving sufficient T cell proliferation, persistence, and functionality within the tumor microenvironment, limiting their overall effectiveness. This can lead to suboptimal patient outcomes and the need for more effective therapeutic strategies.
Solution
Moonlight Bio is developing novel T cell therapies that leverage evolutionary adaptations in human biology to enhance T cell proliferation, persistence, and function. By identifying and incorporating these adaptations, Moonlight Bio aims to create T cell therapies with improved potency and the potential to achieve superior outcomes for cancer patients. The company focuses on the design and screening of these therapies to ensure optimal performance.
Target Audience
The primary target audience includes oncology researchers and clinicians seeking more effective T cell therapies for cancer treatment, as well as pharmaceutical companies interested in licensing or partnering to develop next-generation immunotherapies.
Features
- Identification of evolutionary T cell adaptations within human biology
- Design of T cell therapies incorporating these adaptations
- Screening process to optimize T cell proliferation, persistence, and function
- Focus on enhancing T cell potency for improved cancer treatment